

INDEX

A

- Absorption, distribution, metabolism and excretion
 (ADME).....250
- Acute type.....69, 70
- AD. *See* Atopic dermatitis (AD)
- ADM. *See* Adrenomedullin (ADM)
- Adrenocorticotrophic hormone (ACTH).....143
- Adrenomedullin (ADM).....60, 169
- anticolitis effect175
- CGRP170
- GI tract171
- intestinal epithelial cells171
- intestinal microflora175
- RAMP2170
- Alzheimer's disease (AD).....182
- Amyloid precursor protein (APP)183
- Anesthesia237
- Animal models
- AD.....197, 200
- CTS
- anti-diabetic effect.....190
- P2VO188, 189
- T2VO188, 189
- db/db* mice190, 192
- 5XFAD mice.....200
- YKS
- ameliorative effects185
- intracerebroventricular185
- OBX185
- thiamine-deficient model rats185
- Anorexia
- aging and ghrelin145, 146
- rikkunshito.....146, 147
- Atopic dermatitis (AD)
- eczema113
- Hochu-ekki-to.....127, 128
- IgE-mediated allergy.....114
- pentaherbs capsule127
- superinfections114
- TCM115, 116, 125
- western medicine.....114, 115
- Xiao Feng San.....128, 129
- Zemaphyte.....126
- Atypical dental pain (ADP)75

- Atypical facial pain (AFP)68, 75
- Auscultation and olfaction.....226

B

- Bakumondoto (BMT)239, 240
- Bile flow and biliary secretion213
- Bile formation and secretion207, 208
- Biliary bile acid secretion214
- Biliary tract cancer.....221
- Bilirubin209, 213, 217, 221
- Biophoton analysis system228
- Blood (*Kiketsu Ryokyo*)100, 101
- Burning mouth syndrome (BMS).....68, 71, 72
- Byakkokaninjinto (BNT)74

C

- Calcitonin gene-related peptide (CGRP)60
- ADM171
- CRLR.....170
- DKT-induced hyperemia170
- effective intestinal motility.....172
- endogenous secretion177
- microvascular activities.....171
- microvascular vasodilation169
- neuropeptides169
- vasodilatory actions171
- Canalicular membrane vesicle (CMV)213
- Cancer anorexia–cachexia syndrome
- chemotherapy249
- CRF neurons248
- cytokines247
- gastric vagus nerve248
- ghrelin248
- body weight150
- CRF150, 151
- cytokines150
- gemcitabine249
- GHS-R248
- GHS-R1a agonists151
- herbal medicines.....245
- 5-HT150, 247
- 5-HT2cR247
- hypothermia247
- and leptin secretion245

- Cancer anorexia-cachexia syndrome (*cont.*)
- plasma ghrelin concentrations 150
 - POMC neuron 247
 - quality of life 149
 - secretion 248
 - thromboembolic events 150
 - tumor-bearing rats 245
- radiation therapy 249
- rikkunshito
- BLM-induced lung fibrosis 152
 - gastrointestinal dysmotility 150
 - ghrelin-induced cellular signaling 150
 - 5-HT_{2C} receptor antagonist 150
 - hypothalamic CRF levels 150
- Cancer pain
- CIPN 24, 26, 27
 - dysfunctional 22, 23
 - inflammatory 22
 - neuropathic 23
 - nociceptive 22
 - oral mucositis 27, 28
- Cancer-related fatigue 243
- Capillarisin 219
- CellKey™ system 29
- CGRP. *See* Calcitonin gene-related peptide (CGRP)
- Channel tropism theory 3
- Chemotherapy-induced oral mucositis (COM) ... 27, 243
- Chemotherapy-induced peripheral neuropathy (CIPN)
- Bushi 26
 - GJG 25, 26
 - HJG 26
 - RMG 26
 - shakuyakuzansoto 26
 - yokukansan 27
- Chinese herbal medicine 3
- Chinese herbs 3, 4
- Chinese medicinal herbs
- properties 227, 228
 - tastes and specifications 228–230
- Chinese traditional medicine (CTM). *See* Traditional Chinese medicine (TCM)
- Chinmedomics 230, 231
- Choleretic activities 216
- Choleretic effect 221
- Cholestasis
- definition 208
 - hepatocytes 209
 - Mrp2 expression 209, 210
- Cholinergic systems 189, 191
- Chotosan (CTS)
- blood stasis 186
 - cholinergic systems 189, 191
 - Citrus Unshiu* 195
 - clinical study 186
 - cognitive dysfunction 188–190
 - CTS-treated db/db mice 196, 197
 - defect of Liver 186
 - GPC 196, 198
 - MMSE 186
 - neuroplasticity-related neuronal signaling 192, 193
 - Qi deficiency 186
 - Uncaria* 195
 - VaD patients 186
 - VEGF and PDGF systems 194
 - verbal fluency test 188
- Chronic fatigue syndrome 243
- Chronic obstructive pulmonary disease (COPD) 239
- Chronic type 70
- CIPN. *See* Chemotherapy-induced peripheral neuropathy (CIPN)
- Cisplatin 244
- Cisplatin-induced anorexia
- ghrelin
 - acute and delayed nausea 147
 - chemotherapy-induced gastrointestinal disorders 147
 - disrupted gastrointestinal function 147
 - dyspepsia 147
 - exogenous ghrelin ameliorates anorexia 148
 - gastric emptying 148
 - 5-HT 147
 - 5-HT_{2B}-receptor 147
 - 5-HT_{2C} receptor antagonist 148
 - hypothalamic 5-HT_{2C} receptor gene expression 148
 - hypothalamic ghrelin secretion 148
 - hypothalamic GHS-R1a gene expression 148
 - ICV injection 148
 - intraperitoneal injection 147
- rikkunshito
- ameliorated chemotherapy-induced nausea and vomiting 149
 - ghrelin concentration 149
 - ghrelin secretion 149
 - GHS-R1a expression 149
 - ICV injection 149
 - plasma acyl-ghrelin levels 148
- Colonic vascular conductance (CVC) 60
- Complementary and alternative medicine (CAM) 225, 250
- Constipation
- bowel symptoms 53
 - herbs components 54
 - JHMs 54
 - primary and secondary causes 53
- Constitutive androstane receptor (CAR) 219
- Corticotropin-releasing factor (CRF) 143, 144
- Coughing 239

CRF. *See* Corticotropin-releasing factor (CRF)

Crohn's disease

- acetic acid-induced colonic ulceration 175
- ADM 175
- adrenomedullin 175
- anti-TNF α agents 177
- ASA 178
- CGRP 177
- colonic mucosal flow 177
- DKT 177
- herbal and modern medicine 178
- infliximab 177
- multivariate Cox analysis 178
- proinflammatory cytokine production (TNF α
and IFN γ) 175

Crude drugs 71

CVC. *See* Colonic vascular conductance (CVC)

D

Daikenchuto (DKT) 175, 242

See also Kenchuto-based JHMs

- abdominal bloating and cold sensation 167
- colon surgery 45, 47
- Crohn's disease. *see* Crohn's disease
- dai-ken-chu 167
- 3D-HPLC 168
- enteric microbiota 169
- evidence-based information
 - abdominal bloating and cold sensation 169
 - ADM 169–171
 - CGRP 169–171
 - CRLR 170
 - effective intestinal motility 172
 - GI tract 169, 171
 - intestinal epithelial cells 171
 - microvascular activities 171
 - morphine-induced constipation 172
 - muscarinic receptors (M2R and M3R) 172
 - neuronal cells 171
 - neuropeptides 169
 - nicotinic acetylcholine receptors 172
 - transmembrane domains 170
 - TRPA1 171
 - TRPV1 171
 - vasodilatory actions 171

ginseng radix 167

ginsenoside Rb₁ 167

HAS 167, 168

HBS 168

intestinal motility 44

Japanese pepper 167, 169

jejunal pouch interposition 44, 45

maltose powder 167

pharmacokinetic analysis 169

postoperative ileus 174, 176

prokinetic effect 45, 168

[6]-shogaol 167

synergistic effects, multitargets 172, 173

upper small intestine and liver 169

Dementia

AD 181, 182

Chinese medicines 182

treatment. *see* Kampo therapy

VaD 181

DKT. *See* Daikenchuto (DKT)

Dry mouth 76, 77

Dryness of the mouth 76

Dual deficiency of qi (Ki) 100

E

Evidence-based medicine (EBM) 231

F

Fatigue

condition 98

definition 97, 98

kampo medical diagnosis. *see* Kampo medical diagnosis

pathological fatigue 98

FD. *See* Functional dyspepsia (FD)

FOLFOX therapy 241

Functional dyspepsia (FD) 135, 244

and ghrelin 139, 140

and rikkunshito 140, 141

G

Gastrectomy

ghrelin 152

rikkunshito 152, 153

Gastroesophageal reflux disease (GERD) 135

and ghrelin 141

and rikkunshito 141, 142

Gastrointestinal (GI) surgery

clinical trials 45, 46

DKT. *see* Daikenchuto (DKT)

gastrectomy 38

postoperative complications 38

postoperative ileus 47, 49

RKT. *see* Rikkunshito (RKT)

types 38

Genipin 212–214

Geniposide 212, 216

GERD. *See* Gastroesophageal reflux disease (GERD)

Ghrelin

FD 139, 140

GERD 141, 142

ill patients 153, 154

stress

Ghrelin (*cont.*)

- anxiety and depression 143
- CRF 143, 144
- CRF2 receptors 143
- exogenous acylated-ghrelin ameliorated 144
- food intake 142, 144
- 5-HT2B receptor antagonists 144
- intracerebroventricular administration,
 - mCPP 144
- plasma acylated-ghrelin levels 144
- plasma des-acyl-ghrelin levels 144
- plasma ghrelin concentrations 143
- plasma ghrelin level 142
- psychological/environmental stressors 142
- SB215505 and SB204741 144
- suppression of appetite 143
- Ucn1 143
- Ucn2 143
- Ucn3 143

Ginsenoside Rb₁ 167

GJG. *See* Goshajinkigan (GJG)

Glossalgia 72

Glycerophosphocholine (GPC) 196, 198

Good agricultural and collection practices (GACP) 166

Goshajinkigan (GJG) 25, 241

GPC. *See* Glycerophosphocholine (GPC)

H

Hachimijiogan (HJG) 25, 26

Hangeshasinto 242, 243

HAS. *See* Hydroxy- α -sanshool (HAS)

HBS. *See* Hydroxy- β -sanshool (HBS)

Hepatocellular carcinoma (HCC) 240

Heptamethoxyflavone 244

Herbal medicinal products 250

Herbal medicines 53, 62

High throughput technologies 230

HJG. *See* Hachimijiogan (HJG)

Hochuekkito 243, 244

- chemotherapy 103
- pediatric orthostatic dysregulation 103
- spermatogenic function 107
- tonifying formula 103

Hochuekkito (HET) 72

5-HT2B/2C-receptor antagonism 137

5-HT-regulated ghrelin secretion 151

Hydroxy- α -sanshool (HAS) 168

Hydroxy- β -sanshool (HBS) 168

Hyo Sho-Ri Sho 10

I

Immunoblot analysis 210, 215

Immunostaining 214

Inchinkoto (ICKT)

- capillarasin 219
- chemical analyses 211
- choleric effect 212
- clinical studies 220, 221
- CMVs 214
- effects, chimeric mice 218
- genipin 212, 216
- jaundice and cholestasis 211
- LPS-induced cholestasis 219
- Nrf2-mediated antioxidative actions 217

Information-rich techniques 230

Insomnia 82

Inspection 226

Interrogation 226

Intracerebroventricular (ICV) 148

Irinotecan hydrochloride (CPT-11) 242

Irritable bowel syndrome (IBS) 57

J

Japanese Good Manufacturing Process (GMP) 166

Japanese herbal medicines (JHMs) 54

- constipation 56, 57
- IBS 57
- Kenchuto 56, 57
- KM physicians 57
- medicinal herbs 56
- Rhei Rhizoma-based JHMs 56

Japanese kampo medicine 21, 22

Japanese traditional medicine 54

Jaundice 208

- obstructive jaundice 221
- treatment. *see* Inchinkoto (ICKT)

JHMs. *See* Japanese herbal medicines (JHMs)

Jitsu Sho-Kyo Sho 10

Juzentaihoto 240, 241

- anticancer drug-induced cytotoxicity 108
- cancer radiation therapy 108
- cellular immunity 108
- chemotherapy 107
- leukocytopenia 107
- marrow and immunostimulatory effects 109
- prevention 107
- thrombocytopenia 108

K

Kamishoyosan (KSS) 72

Kampo diagnosis, Sho

- oketsu syndrome 11
- solid viscera 13
- stages of disease. *see* Stages of disease, Kampo
- Yin-Yo, Jitsu-Kyo, Kan-Netsu and Hyo-Ri 9, 10

Kampo medical diagnosis

- analytical approach 98
- Astragalus root (Ogi) 102
- blood
- deficiency symptoms 104
 - and fluid 99
 - Kiketsu Ryokyo* 100
 - tonifying formulation 105
- characteristic features 99
- crude drugs 105
- Ginseng (Ninjin) 102
- hochuekkito 103, 104, 107
- juzentaihoto 104, 107–109
- liver [TM] regulates 104
- predominant formulation 105
- qi (Ki) deficiency 99, 100
- treatments 101
- Kampo medicine (KM)
- abnormal Qi patterns, types 55
 - anesthesia 237
 - chronic health conditions 55
 - clinical diagnosis 82
 - composition 83
 - constipation 56
 - 3D HPLC analysis 238
 - diagnosis (Sho) 238
 - evidence-based approach 55
 - examination methods 56
 - ghrelin 239
 - holistic medicine 54
 - hormone therapy 82
 - host's inherent ability 55
 - isolation, identification and analysis 238
 - Japan's health care system 54
 - JHMs 54
 - Keishibukuryogan, blood pressure
 - cardiovascular parameters 87, 88
 - cholesterol-fed rabbits 88
 - components 87
 - CVD 86
 - mechanism 87
 - menopausal symptoms 89
 - systolic pressure 87
 - treatment 86
- medical education program 55
- palliative care 238
- personalized medicine 239
- Qi deficiency 56
- sleep disturbances 82–86
- TCM 54, 55, 237
- TSS
- community and primary care settings 89
 - headaches and depression 91, 92
 - Ligusticum chuanxiang* 93
 - menopausal symptoms 89
 - migraine 91
 - peri- and postmenopausal women 90
 - psychological symptoms 89
 - somatization 91
 - types 89
 - western and Asian medicines 55
- Kampo theory 68, 69
- Kampo therapy
- anatomic compartments 72
 - animal models 183
 - autonomic nervous system 68
 - BPSD 183
 - clinical and preclinical studies 183
 - cranial nerve system 68
 - CTS. *see* Chotosan (CTS)
 - KKT 191, 200
 - oral cavity 68
 - YKS
 - animal models, dementia 183, 185
 - BPSD 183
 - defect of Liver 183
 - neuroprotective effect 187
 - OBX 185
 - Uncariae Uncis cum Ramulus* 187
- KCNK channels 172
- Keishikaryukotuboreito (KRB) 75
- Kenchuto-based JHMs 57
- clinical application 61, 62
 - CVC 60
 - DKT 59, 60
 - enterochromaffin cells 59
 - ginger 59, 60
 - ginseng radix 59, 60
 - glycyrrhizin 61
 - herbs 59
 - hydroxy-sanshools 60
 - keishikashakuyakuto 61
 - nicotinic acetylcholine receptors 59
 - pharmacology 61, 62
 - Saccharum Granorum* 59
 - shokenchuto 62
 - TRPV1 60
 - Zanthoxyli Fructus* 59
- Kihi-to and kami-kihi-to (KKT)
- animal models 197, 199, 200
 - Bupleurum falcatum* 191
 - cognitive/learning dysfunction 191
 - Gardenia jasminoides* 191
- Ki, Ketsu and Sui theory 68, 69
- Ki-kyo and ketsu-kyo 10
 - Ki-utsu and Ki-gyaku 10
 - O-ketsu and sui-tai 10, 11
- Kikyoto (KKT) 74
- Kyo-jitsu 17

L

Levodopa 155, 156
Liu-Wei-Di-Huang (LWDH) formula 233

M

Menopausal symptoms. *See* Kampo medicine (KM)
Mesolimbic dopamine system (MDS) 71
Mini mental state examination (MMSE) 186
MMSE. *See* Mini mental state examination (MMSE)
Molecular mechanism 192, 194
Mrp2 expression
 genipin-induced change 216
 immunoblot analysis 210, 215
 immunoelectron microscopy analysis 215
 immunostaining 214, 215
 microvilli 216

N

Netsu Sho-Kan Sho 10
Network pharmacology 232, 233
N-methyl-D-aspartate receptor (NMDAR) 192

O

OBX-induced spatial working memory deficit ... 185, 186
Odontopathy 70
O-Ketsu and Sui-Tai 10, 11
Olfactory bulbectomy (OBX) 185
Omics techniques 230
Oxaliplatin therapy 241

P

Pain
 approaches 20, 21
 cancer. *see* Cancer pain
 CellKey™ assay system 30
 control 74, 75
 electrical biosensors 28, 29
 Japanese kampo medicine 21, 22
 meta-analysis 20
 treatment 20, 24
 types 19
 western-oriented drugs 23
Palpation 226
Parenchymatous viscera theory 69
Percutaneous transhepatic biliary drainage (PTBD) ... 210
Period of Jin and Yuan Dynasty 5
Period of Ming and Ching Dynasty 5, 6
Phosphodiesterase 3 (PDE3) 146
Pirfenidone 155
Post-gastrectomy syndromes
 gastrointestinal hormones 41
 mechanism 43

 proximal gastrectomy 43
 QOL assessments 43
Postoperative ileus (POI) 174–176, 242
PPG. *See* Pylorus-preserving gastrectomy (PPG)
Prostaglandin E2 (PGE2) 242
Proximal gastrectomy (PG) 153
Psychosomatic pattern
 in AFP and ADP 76
 depressive state 75
 herbal medicines 75
 in Shoyoby stage 75
Pylorus-preserving gastrectomy (PPG) 153
 dual-phase scintigraphy 41
 GIQLI 40

Q

Qi (Ki) deficiency 99, 100
QOL. *See* Quality of life (QOL)
Quality of life (QOL) 38

R

Radix Scutellariae 3
Randomized controlled trials (RCTs) 231
Rhei-Rhizoma-based JHMs 56
 alimentary tract 58
 anhidrous mirabilitum 58
 bofutsushosan 58
 cannabis fructus 58
 Daiokanzoto 57, 58
 dianthrone glycosides 57
 5-FU 58
 Glycyrrhizae radix 57
 herbs, constipation 57
 junchoto and mashingan 58
 mashingan soften stool 58
 Rhei Rhizoma 57
 sennosides A and B 57
 Tokakujokito 58
 Tsudosan 58
Rhizoma Coptidis 3
Rikkunshito (RKT)
 anorexia 245
 cisplatin 244
 cisplatin-induced anorexia 148, 149
 FD 135, 140, 141, 244
 GERD 135, 141, 142
 herbal medicines 40
 5-HT 245
 ill patients 154
 ingredients 245
 Japanese pharmacopoeia 244
 kampo herbal medicine 135
 leptin 246

pharmacology	
ghrelin enhancer.....	137, 138
pharmacokinetics.....	138, 139
prokinetic agent.....	136, 137
post-gastrectomy syndromes.....	41, 43
PPG.....	40, 41
prokinetic activity.....	135
serial changes.....	41, 42
SSRI.....	244, 245
on stress.....	143, 145
treatment.....	40
upper gastrointestinal symptoms.....	135
RKT. <i>See</i> Rikkunshito (RKT)	
RMG. <i>See</i> Rokumigan (RMG)	
Rokumigan (RMG).....	25, 26

S

Saikokaryukotsuboreito (SRB).....	75
Selective serotonin reuptake inhibitor (SSRI).....	154, 155, 244
Serotonin type-3 receptors.....	136
Shakuyakukanzoto.....	241
Shi-shin	
inquiry (Monshin).....	14
listening and smelling (Bunshin).....	14
palpation (Sessin).....	14–17
visual observation (Boshin).....	13–15
Sho. <i>See</i> Kampo diagnosis, Sho	
[6]-Shogaol.....	171
Sho Yin stage.....	13
Single nucleotide polymorphisms (SNPs).....	140
Sinusoidal and canalicular membrane transporters.....	208
Spring and autumn warring state period.....	4
Stages of disease, Kampo	
Ketu Yin stage.....	13
Sho Yo stage.....	11, 12
Tai Yo stage.....	11
TaiYin stage.....	12
YoMei stage.....	12
Stomatitis.....	69
Symptoms of abnormality.....	73, 74
Syndrome differentiation.....	2

T

Taste abnormality	
intense astringency.....	78
intense bitterness.....	77, 78
intense sweetness.....	78
Taste loss.....	78
TCM. <i>See</i> Traditional Chinese medicine (TCM)	
Temporomandibular disorder (TMD).....	78, 79
The Han Dynasty.....	4

The seven relations theory.....	3
The Tang Dynasty.....	5
Thirst (heat and dryness pattern).....	76
Three-dimensional high-performance liquid chromatography (3D HPLC) analysis.....	238
Tokishakuyakusan (TSS).....	72
community and primary care settings.....	89
headaches and depression.....	91, 92
Ligusticum chuanxiong.....	93
menopausal symptoms.....	89
migraine.....	91
peri- and postmenopausal women.....	90
psychological symptoms.....	89
somatization.....	91
types.....	89
Traditional Chinese medicine (TCM).....	54
Asian populations.....	234
atopic dermatitis.....	116
auscultation and olfaction.....	226
CAM.....	225
chinmedomics.....	230, 231
CHM treatments.....	116
clinical studies.....	125
clinical trials.....	231, 232
crude herbs.....	227
decoctions.....	227
dermatological conditions.....	116, 117
diagnosis.....	2, 226
ethnobotanical therapy.....	115
fetal heat.....	115
inspection.....	226
internal pathogenic factors.....	115, 116
interrogation.....	226
Kampo.....	237
mechanisms.....	227
network pharmacology.....	232, 233
original use.....	1
palpation.....	226
patients symptoms and signs.....	226
powder preparation.....	227
Yin-Yang theory.....	225
Transient receptor potential ankyrin 1 (TRPA1).....	171, 172
Transient receptor potential vanilloid receptor-1 (TRPV1).....	71, 171
Translational research.....	250
TRPV1. <i>See</i> Transient receptor potential vanilloid receptor-1 (TRPV1)	

U

Urocortin1 (Ucn1).....	143
Urocortin3 (Ucn3).....	143

V

Vascular dementia (VaD)
 anti-VaD drug 182
 risk factors..... 182
 VEGF and PDGF systems 194
 Verbal fluency test 186

W

Western blotting method 214, 221
 WHO. *See* World Health Organization (WHO)
 World Health Organization (WHO) 125

Y

Yin-Yang theory 225
 Yin/Yo theory 9–11, 17, 68

Y-maze test 186
 Yokukansan (YKS)..... 75
 ameliorative effects 185
 animal models, dementia 183, 185
 BPSD 183
 defect of Liver 183
 neuroprotective effect 187
 OBX 185
Uncariae Uncis cum Ramulus 187
 Y-maze test 186
 Yokukansankachinpihange (YKSCH) 75
 Yo Sho–Yin Sho 9

Z

ZHENG classification 226